Attached files
| file | filename |
|---|---|
| 10-K - KERYX BIOPHARMACEUTICALS INC | v178368_10k.htm |
| EX-21.1 - KERYX BIOPHARMACEUTICALS INC | v178368_ex21-1.htm |
| EX-32.1 - KERYX BIOPHARMACEUTICALS INC | v178368_ex32-1.htm |
| EX-32.2 - KERYX BIOPHARMACEUTICALS INC | v178368_ex32-2.htm |
| EX-31.1 - KERYX BIOPHARMACEUTICALS INC | v178368_ex31-1.htm |
| EX-23.1 - KERYX BIOPHARMACEUTICALS INC | v178368_ex23-1.htm |
| EX-31.2 - KERYX BIOPHARMACEUTICALS INC | v178368_ex31-2.htm |
Exhibit
23.2
Consent of Independent
Registered Public Accounting Firm
The Board
of Directors
Keryx
Biopharmaceuticals, Inc.:
We
consent to the incorporation by reference in the following registration
statements of Keryx Biopharmaceuticals, Inc., of our report dated March 31,
2009, with respect to the consolidated balance sheet of Keryx
Biopharmaceuticals, Inc. and subsidiaries as of December 31, 2008, and the
related consolidated statements of operations, stockholders’ (deficiency)
equity, and cash flows for each of the years in the two-year period ended
December 31, 2008, which report appears in the December 31, 2009 annual report
on Form 10-K of Keryx Biopharmaceuticals, Inc.:
|
|
-
|
Form
S-8 dated February 5, 2001 (File No.
333-55006)
|
|
|
-
|
Form
S-3 dated December 12, 2003, as amended (File No.
333-111143)
|
|
|
-
|
Form
S-8 dated September 29, 2004 (File No.
333-119377)
|
|
|
-
|
Form
S-3 dated March 16, 2004, as amended (File No.
333-113654)
|
|
|
-
|
Form
S-3 dated April 19, 2004 (File No.
333-114593)
|
|
|
-
|
Form
S-3 dated September 29, 2004 (File No.
333-119376)
|
|
|
-
|
Form
S-3 dated July 11, 2005 (File No.
333-126494)
|
|
|
-
|
Form
S-3 dated December 30, 2005 (File No.
333-130809)
|
|
|
-
|
Form
S-3 dated April 6, 2006, as amended (File No.
333-133051)
|
|
|
-
|
Form
S-8 dated April 6, 2006, as amended (File No.
333-133052)
|
|
|
-
|
Form
S-3/A dated June 21, 2006 (File No.
333-133051)
|
|
|
-
|
Form
S-8 dated July 31, 2007 (File No. 333-145003);
and
|
|
|
-
|
Form
S-3 dated August 28, 2009 (File No.
333-161607).
|
Our
report dated March 31, 2009 contains an explanatory paragraph that states that
the Company has incurred substantial recurring losses from operations, a
deficiency in equity, has limited cash, cash equivalents, and short term
securities, and illiquid investments in auction rate securities that raise
substantial doubt about its ability to continue as a going concern. The
consolidated financial statements and financial statement schedules do not
include any adjustments that might result from the outcome of that
uncertainty.
Our
report also refers to the Company’s adoption of an accounting standard issued by
the Financial Accounting Standards Board for the fair value of financial assets
and liabilities in 2008.
/s/ KPMG
LLP
New York,
New York
March 25,
2010